KOD - Latest News
Kodiak Sciences Inc. (KOD), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $2.59B. Beta to the broader market is 2.21.
The article list below shows the most recent KOD headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent KOD Headlines
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
zacks.com - Aug 14, 2026
KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
prnewswire.com - Aug 13, 2026
PALO ALTO, Calif. , Aug.
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
zacks.com - Aug 11, 2026
Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
prnewswire.com - Aug 10, 2026
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema PALO ALTO, Calif. , Aug.
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
prnewswire.com - Aug 6, 2026
First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 release Completion of
How News Affects KOD Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track KOD's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked KOD news questions
- What is the latest KOD news headline?
- The most recent KOD headline (Aug 14, 2026) is "Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the KOD news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What KOD news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual KOD options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.